Synapse
Synapse×AmericanHeartAssociation®

AHA Scientific Sessions 2026 Late-Breaking Science — American Heart Association, Chicago

22 late-breaking presentations across 6 Late-Breaking Science sessions at AHA Scientific Sessions 2026 in Chicago, 7-9 November. Each trial includes PICO analysis, expert commentary, key results, and clinical implications.

AHA Scientific Sessions 2026 Late-Breaking Science Results — every trial's key result on one page

  1. ZEUS: Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS) — Prevention
  2. Lp(a)HORIZON: Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial — Lipids
  3. Lp(a)HORIZON Extended Analyses: Extended analyses of cardiovascular outcomes with pelacarsen treatment in the Lp(a)HORIZON trial — Lipids
  4. OCEANIC-STROKE: FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial — Stroke
  5. REDUCE: A randomized controlled trial of spironolactone-based blood pressure management after stroke (REDUCE) — Stroke
  6. OPTIMAL-Stroke: Intensive blood-pressure control for the prevention of major cardiovascular events in patients with prior stroke: the OPTIMAL-Stroke trial — Stroke
  7. STREAM: Discontinuing statins in multimorbid older adults without cardiovascular disease: a randomized non-inferiority clinical trial (STREAM) — Prevention
  8. OPTIMAL-DIABETES: Intensive blood pressure control for the prevention of major cardiovascular events in patients with type 2 diabetes: the OPTIMAL-DIABETES trial — Hypertension
  9. eZ-PAVE: Statin-ezetimibe combination therapy versus statin monotherapy in patients with atherosclerotic cardiovascular disease: pre-specified second randomization of the eZ-PAVE trial — Lipids
  10. Yoga-CaRe HF: Yoga-based cardiac rehabilitation in heart failure with reduced ejection fraction (Yoga-CaRe HF) — Heart Failure
  11. OptimPacing: Left bundle branch pacing versus right ventricular pacing for atrioventricular block: an international multi-center randomized controlled trial (OptimPacing) — Devices & Arrhythmias
  12. COAST-AF Randomized: Characterization of arrhythmia substrate to ablate persistent atrial fibrillation: the COAST-AF randomized trial — Atrial Fibrillation
  13. SUPERIOR: Sacubitril/valsartan for preventing recurrence of atrial fibrillation after catheter ablation in patients with hypertension: a multicenter, randomized controlled trial (SUPERIOR) — Atrial Fibrillation
  14. RACE-CARS: Randomized cluster evaluation of cardiac arrest systems (RACE-CARS) trial: primary results — Acute Cardiac Care
  15. TYDAL-TIMI 78: A randomized trial of ANGPTL4 inhibition with MAR001 in adults with elevated triglycerides and remnant cholesterol concentrations (TYDAL-TIMI 78) — Lipids
  16. CTX310: CRISPR-Cas9 gene editing therapy targeting ANGPTL3 for severe hypertriglyceridemia: results from a phase 1b trial (CTX310) — Lipids
  17. ATTAIN-OSA: Orforglipron for the treatment of obstructive sleep apnea: results from ATTAIN-OSA — Cardiometabolic
  18. SYNCHRONIZE-CVOT: Survodutide and cardiovascular outcomes in obesity: results from the SYNCHRONIZE-CVOT trial — Cardiometabolic
  19. WATCH-LV: Consumer smartwatch artificial intelligence-enabled electrocardiogram for left ventricular systolic dysfunction: cross-manufacturer validation and serial home monitoring (WATCH-LV) — Digital Health
  20. PROVAR+: AI-enabled tele-ECG identifies structural heart disease and prioritizes echocardiography in underserved populations: the PROVAR+ external validation study — Digital Health
  21. AI-Echo RCT: AI-assisted comprehensive echocardiographic interpretation: a blinded, randomized controlled trial — Imaging
  22. AI Plaque + FFR-CT: All-cause and cardiovascular mortality in the U.S.: risk stratification via integrated AI-enabled coronary plaque analysis and FFR-CT in over 269,000 patients (LIFE-AI Study) — Imaging
Stroke

REDUCE

A randomized controlled trial of spironolactone-based blood pressure management after stroke (REDUCE)

Jordana Cohen

Stroke

OPTIMAL-Stroke

Intensive blood-pressure control for the prevention of major cardiovascular events in patients with prior stroke: the OPTIMAL-Stroke trial

Gisele Sampaio

Prevention

STREAM

Discontinuing statins in multimorbid older adults without cardiovascular disease: a randomized non-inferiority clinical trial (STREAM)

Nicolas Rodondi

Hypertension

OPTIMAL-DIABETES

Intensive blood pressure control for the prevention of major cardiovascular events in patients with type 2 diabetes: the OPTIMAL-DIABETES trial

Karla Santo

Paul Ridker

Mass General Brigham Hospital, Boston, USA

Steven Nissen

Cleveland Clinic Foundation, Cleveland, USA

Nicolas Rodondi

Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland

Byeong-Keuk Kim

Yonsei University Severance Hospital, Seoul, Republic of Korea

Carolina Malta Hansen

Copenhagen EMS, Ballerup, Denmark

Michelle O'Donoghue

Brigham and Women's Hospital, Boston, USA

Prevention

ZEUS

Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

Paul Ridker

Lipids

Lp(a)HORIZON

Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial

Steven Nissen

Lipids

Lp(a)HORIZON Extended Analyses

Extended analyses of cardiovascular outcomes with pelacarsen treatment in the Lp(a)HORIZON trial

Steven Nissen

Stroke

OCEANIC-STROKE

FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial

Mukul Sharma

Synapse
Synapse×AmericanHeartAssociation®

November 7–9

Discuss AHA 2026 trials with the authors.

Explore the findings. Ask your questions. Hear directly from the researchers behind the trials.

This year's late-breakers

  • Prevention

    ZEUS

    Primary report of the ziltivekimab cardiovascular outcomes trial (ZEUS)

    Paul Ridker

  • Lipids

    Lp(a)HORIZON

    Effect of pelacarsen on cardiovascular outcomes in patients with elevated lipoprotein(a): primary results from the Lp(a)HORIZON trial

    Steven Nissen

  • Lipids

    Lp(a)HORIZON Extended Analyses

    Extended analyses of cardiovascular outcomes with pelacarsen treatment in the Lp(a)HORIZON trial

    Steven Nissen

  • Stroke

    OCEANIC-STROKE

    FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial

    Mukul Sharma

5K+

Join thousands of cardiologists on Synapse

  • Stanford
  • UCLA
  • OPCI
  • U Miami

The trial authors

From the late-breakers' author lists. Authors on Synapse are marked.

  • Paul Ridker

    Paul Ridker

    General · Preventive · Lipids

    ZEUS

  • Biykem Bozkurt

    Biykem Bozkurt

    Heart Failure · Cardiomyopathy

    SYNCHRONIZE-CVOT

  • Steven Nissen

    Steven Nissen

    General · Preventive · Lipids

    Lp(a)HORIZON

  • Nicolas Rodondi

    Nicolas Rodondi

    General · Preventive · Lipids

    STREAM